IRLAB Therapeutics Future Growth
Future criteria checks 0/6
Se prevé que los ingresos deIRLAB Therapeutics aumenten en 1.5% al año. Se prevé que el BPA de decline sea de 3.2% al año.
Key information
n/a
Earnings growth rate
-3.2%
EPS growth rate
| Pharmaceuticals earnings growth | 49.2% |
| Revenue growth rate | 1.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 25 Mar 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04
Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2024 | 24 | -119 | N/A | -90 | 2 |
| 12/31/2023 | 6 | -178 | -165 | -165 | N/A |
| 9/30/2023 | 19 | -176 | -169 | -169 | N/A |
| 6/30/2023 | 36 | -162 | -163 | -160 | N/A |
| 3/31/2023 | 52 | -144 | -155 | -151 | N/A |
| 12/31/2022 | 61 | -113 | -146 | -143 | N/A |
| 9/30/2022 | 61 | -103 | -136 | -133 | N/A |
| 6/30/2022 | 240 | 42 | 96 | 98 | N/A |
| 3/31/2022 | 217 | 43 | 117 | 118 | N/A |
| 12/31/2021 | 208 | 52 | 128 | 129 | N/A |
| 9/30/2021 | 196 | 55 | 140 | 141 | N/A |
| 6/30/2021 | 0 | -93 | -93 | -92 | N/A |
| 3/31/2021 | N/A | -93 | -88 | -87 | N/A |
| 12/31/2020 | 0 | -92 | -90 | -89 | N/A |
| 9/30/2020 | 0 | -99 | -99 | -99 | N/A |
| 6/30/2020 | 0 | -93 | -93 | -92 | N/A |
| 3/31/2020 | 1 | -98 | -98 | -98 | N/A |
| 12/31/2019 | 0 | -96 | -91 | -91 | N/A |
| 9/30/2019 | 1 | -88 | -83 | -83 | N/A |
| 6/30/2019 | 1 | -83 | -78 | -78 | N/A |
| 3/31/2019 | 0 | -76 | -75 | -75 | N/A |
| 12/31/2018 | 0 | -74 | -72 | -71 | N/A |
| 9/30/2018 | 0 | -68 | -76 | -75 | N/A |
| 6/30/2018 | 0 | -73 | -68 | -67 | N/A |
| 3/31/2018 | 0 | -60 | -59 | -58 | N/A |
| 12/31/2017 | 0 | -56 | -58 | -58 | N/A |
| 9/30/2017 | 0 | -58 | N/A | -48 | N/A |
| 6/30/2017 | 0 | -48 | N/A | -45 | N/A |
| 3/31/2017 | 3 | -44 | N/A | -45 | N/A |
| 12/31/2016 | 3 | -43 | N/A | -41 | N/A |
| 12/31/2015 | 3 | -12 | N/A | -28 | N/A |
| 12/31/2014 | 3 | 3 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de IRLAB A es superior a la tasa de ahorro (0.9%).
Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de IRLAB A crezcan más deprisa que el mercado Swedish
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de IRLAB A crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: IRLAB A(1.5% al año) se prevé que crezca más despacio que el mercado de Swedish (2.2% al año).
Ingresos de alto crecimiento: IRLAB ASe prevé que los ingresos de la empresa (1.5% al año) crezcan más despacio que 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de IRLAB A se prevé elevada dentro de 3 años.